Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
Giacomo P. Comi(Vita-Salute San Raffaele University), Massimo Filippi(Vita-Salute San Raffaele University), Sámuel Komoly(University of Pecs), Krzysztof Selmaj(University of Warmia and Mazury in Olsztyn), Marco Rovaris(San Raffaele University of Rome), Ralf Gold(University Hospitals of the Ruhr-University of Bochum), Eva Havrdová(Charles University), Oded Abramsky, T. Arbizu(Bellvitge University Hospital), Basil Sharrack(Sheffield Teaching Hospitals NHS Foundation Trust), А. Н. Бойко(Vladivostok State Medical University), Annalisa Pulizzi
Cited by 276
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k